Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

AVROBIO, Inc. AVRO NASDAQ

NASDAQ Global Select • Healthcare • Biotechnology • US • USD

SharesGrow Score
31/100
0/5 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow

AVROBIO, Inc. (AVRO) is a Biotechnology company in the Healthcare sector, currently trading at $1.40. It has a SharesGrow Score of 29/100, indicating a weak investment profile with 0 out of 7 criteria passed.

Net income is $74M (loss), growing at -164.5%/yr. Net profit margin is 0% (thin). Gross margin is 0% (+0 pp trend).

Balance sheet: total debt is $1M against $251M equity (Debt-to-Equity (D/E) ratio 0.01, conservative). Current ratio is 26.63 (strong liquidity). Debt-to-assets is 0.5%. Total assets: $261M.

Analyst outlook: 4 / 10 analysts rate AVRO as buy (40%) — mixed sentiment.

SharesGrow 7-Criteria breakdown: Value ?/100 (Fail), Growth 15/100 (Fail), Past 25/100 (Fail), Health 67/100 (Partial), Moat 28/100 (Fail), Future 20/100 (Fail), Income ?/100 (Fail).

AVRO SharesGrow Score Overview

31/100
SharesGrow Score
Below average — proceed with caution
View full scorecard →
VALUE 0/100
Valuation — P/E, PEG, Forward PEG
GROWTH 15/100
Financials — average growth
PAST 25/100
strong — trend
HEALTH 67/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 28/100
Gross margin is + market cap
FUTURE 20/100
Analyst outlook — as buy
INCOME 0/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — AVRO

—
VALUE N/A
N/A
No analyst coverage available for this stock.
✗
GROWTH Fail
15/100
AVRO: +0%/yr revenue is, -164.5%/yr Net income is average growth. weak. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
✗
PAST Fail
25/100
AVRO: 1 / 4 years profitable. weak. Score = 1 / 4 × 100. ≥ 80 = Pass.
View details →
~
HEALTH Partial
67/100
Balance sheet AVRO: Debt-to-Equity (D/E) ratio 0.01 (conservative), Current ratio is 26.63 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
✗
MOAT Fail
28/100
AVRO: Gross margin is 0% (+0 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 28/100. ≥ 70 = Pass.
View details →
✗
FUTURE Fail
20/100
Analyst outlook: 4 / 10 analysts rate AVRO as buy (40%). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.
View details →
—
INCOME N/A
N/A
No analyst coverage available for this stock.

Stock Chart & Stats

Market Data
52-Week Range1.38-19.8
Volume204.38K
Avg Volume (30D)19.05K
Market Cap$5.24M
Beta (1Y)1.22
Share Statistics
EPS (TTM)-4.05
Shares Outstanding$18.32M
IPO Date2018-06-21
Employees13
CEOErik John Ostrowski
Financial Highlights & Ratios
EBITDA$-71.48M
Net Income$-74.15M
Operating Income$-84.04M
Total Cash$253.8M
Total Debt$1.28M
Net Debt$-252.52M
Total Assets$261.04M
Price / Earnings (P/E)-0.3
Analyst Forecast
Rating ConsensusHold
Analysts Covering10
Buy 40% Hold 60% Sell 0%
Company Info
CountryUS
ExchangeNASDAQ Global Select
CurrencyUSD
ISINUS05455M1009

Price Chart

Track all markets on TradingView
AVRO
AVROBIO, Inc. ↗  ·  NASDAQ Global Select
Healthcare • Biotechnology
1.38 52WK RANGE 19.80

People Also View

ZURA
ZURA
Zura Bio Limited
$5.72
+0.70%
 ELEV
ELEV
Elevation Oncology, Inc.
$0.37
-2.12%
 CWBR
CWBR
CohBar, Inc.
$0.41
+0.00%
 ENVB
ENVB
Enveric Biosciences, Inc.
$1.95
-1.02%
 HEPA
HEPA
Hepion Pharmaceuticals, Inc.
$0.05
+18.52%
 OCEA
OCEA
Ocean Biomedical, Inc.
$0.00
+0.00%
 EFTR
EFTR
eFFECTOR Therapeutics, Inc.
$0.00
+0.00%
 LLY
LLY
Eli Lilly and Company
$922.50
-0.76%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message